HFK2 / HighField Bio - LARVOL DELTA

HighField Biopharmaceuticals Files INDs for Two ADCplex Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs (Businesswire) - "HighField Biopharmaceuticals...announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with China’s National Medical Products Administration for immunoliposomes carrying different cancer killing payloads....HF158K1 (K1) and HFK2 (K2) are both fitted with HER2 antibodies for binding to cancer cell surface HER2 receptors in both HER2 high and low tumors. K1 is being evaluated as a monotherapy in an ongoing Phase 1 trial in the US (NCT05861895). The planned Phase 1 open label, dose escalation trial of K1 and K2 in China will evaluate the safety and pharmacokinetics of K1 as a monotherapy and preliminary efficacy in combination with K2."

New P1 trial • Trial status • Solid Tumor